Sanofi Sells French Rights of Four Treatments to Merus Labs

Feb 24, 2016

Merus Labs International Inc. has entered into an agreement with Sanofi S.A. to acquire the rights to Surgestone, Provames, Speciafoldine, and Tredemine in France for about $24.8 million.

Surgestone and Provames are used in a variety of women’s health indications; Speciafoldine is used to treat macrocytic anemia; and Tredemine is tapeworm medicine.

"We have acquired nine established products over the last ten months and continue to leverage our scalable commercial platform in Europe," said Barry Fishman, Merus CEO.

The acquisition is expected to close during the second week in March 2016.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments